Vision-Related Quality of Life among Patients with Different Types of Age-Related Macular Degeneration

Abstract

Background This study aimed to assess the vision-related quality of life (VRQol) of patients with age-related macular degeneration (AMD) and to evaluate VRQol according to different types of AMD.

Methods In this small-scale, single-center, prospective investigation, patients with AMD and subjects without any signs of macular disease were asked to complete the NEI-VFQ-39. A total of 159 subjects were included and grouped according to the type of AMD as follows: 40 patients with dry AMD in both eyes (DD), 40 patients with exudative AMD in one eye (DE), 41 patients with exudative AMD in both eyes (EE), and 38 subjects without any signs of macular disease, as a control group (CG).

Results The average age of the participants was 76 ± 7 years, and 44% were male. Most participants were retired (22.4%), and 75% of patients were initially diagnosed by their ophthalmologist. All the AMD groups had significantly worse overall VRQol than the CG. For general vision, near vision, mental health, and role difficulties, all the AMD groups had significantly lower scores than the CG. For distance vision, color vision, peripheral vision, driving difficulties, dependency, and social functioning, only patients in the EE and DE groups had significantly worse scores than the CG. The type of retinal fluid in patients with exudative AMD had no effect on overall VRQol; however, we found that the presence of pigment epithelial detachment could be associated with more role difficulties, such as completing work or working long hours.

Conclusion All types of AMD had a negative effect on vision-related quality of life. This effect was significantly more pronounced in patients with exudative AMD in at least one eye. However, the type of retinal fluid in patients with exudative AMD had no influence on their overall vision-related quality of life.

Zusammenfassung

Hintergrund Ziel dieser Studie war es, die visuelle Lebensqualität (VRQol) von Patienten mit altersbedingter Makuladegeneration (AMD) zu beurteilen und die VRQol nach verschiedenen AMD-Typen zu bewerten.

Methoden In dieser kleinen, prospektiven Studie wurden Patienten mit AMD und Probanden ohne Anzeichen einer Makulaerkrankung gebeten, den NEI-VFQ-39 auszufüllen. Insgesamt 159 Probanden wurden eingeschlossen und je nach nach der Art der AMD wie folgt eingeteilt: 40 Patienten mit trockener AMD in beiden Augen (DD), 40 Patienten mit exsudativer AMD in einem Auge (DE), 41 Patienten mit exsudativer AMD in beiden Augen (EE) und 38 Probanden ohne Anzeichen einer Makulaerkrankung als Kontrollgruppe (CG).

Ergebnisse Das Durchschnittsalter der Teilnehmer betrug 76 ± 7 Jahre und 44% waren männlich. Die meisten Teilnehmer waren im Ruhestand (22,4%), und bei 75% der Patienten wurde die Erstdiagnose von ihrem Augenarzt gestellt. Alle AMD-Gruppen hatten einen signifikant schlechteren Gesamt-VRQol als die CG-Gruppe. In den Bereichen allgemeines Sehen, Nahsehen, psychische Gesundheit und Rollenschwierigkeiten wiesen alle AMD-Gruppen signifikant niedrigere Werte auf als die CG-Gruppe. Für Fernsicht, Farbensehen, peripheres Sehen, Fahrschwierigkeiten, Abhängigkeit und soziales Funktionieren hatten nur die Patienten in den Gruppen EE und DE signifikant schlechtere Werte als die CG-Gruppe. Die Art der Netzhautflüssigkeit bei Patienten mit exsudativer AMD hatte keine Auswirkung auf den Gesamt-VRQol; wir fanden jedoch heraus, dass das Vorhandensein einer Pigmentepithelablösung mit mehr Schwierigkeiten bei der Ausübung von Tätigkeiten, wie z. B. dem Erledigen von Arbeiten oder langen Arbeitszeiten, verbunden sein könnte.

Schlussfolgerung Alle Arten von AMD hatten einen negativen Einfluss auf die visuelle Lebensqualität. Dieser Effekt war bei Patienten mit exsudativer AMD an mindestens einem Auge deutlich stärker ausgeprägt. Allerdings hatte die Art der Netzhautflüssigkeit bei Patienten mit exsudativer AMD keinen Einfluss auf die allgemeine visuelle Lebensqualität.

Conclusion Box

Already known:

• All types of AMD had a negative effect on vision-related quality of life.

• In the literature, the vision-related quality of life was not differentiated according to the type of AMD or type of retinal fluid.

Newly described:

• This negative effect was significantly more pronounced in patients with exudative AMD in at least one eye.

• The type of retinal fluid in patients with exudative AMD had no influence on their overall vision-related quality of life. However, the presence of pigment epithelial detachment could be associated with significantly more role difficulties.

Key words

NEI-VFQ-39 - retinal fluid - age-related macular degeneration - quality of life

Schlüsselwörter

NEI-VFQ-39 - altersbedingte Makuladegeneration - retinale Flüssigkeit - Lebensqualität

Publication History

Received: 05 June 2023

Accepted: 13 July 2023

Article published online:
06 September 2023

• References

• 1 Li JQ, Welchowski T, Schmid M. et al. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol 2020; 104: 1077-1084 DOI: 10.1136/bjophthalmol-2019-314422.
• 2 Colijn JM, Buitendijk GHS, Prokofyeva E. et al. Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future. Ophthalmology 2017; 124: 1753-1763 DOI: 10.1016/j.ophtha.2017.05.035.
• 3 Jonas JB, Cheung CMG, Panda-Jonas S. Updates on the epidemiology of age-related macular degeneration. Asia Pac J Ophthalmol (Phila) 2017; 6: 493-497 DOI: 10.22608/APO.2017251.
• 4 Ferris FL3rd Wilkinson CP, Bird A. et al. Clinical classification of age-related macular degeneration. Ophthalmology 2013; 120: 844-851 DOI: 10.1016/j.ophtha.2012.10.036.
• 5 Mathis T, Holz FG, Sivaprasad S. et al. Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes. Eye (Lond) 2023; 37: 1758-1765 DOI: 10.1038/s41433-022-02231-y.
• 6 Inan S, Cetinkaya E, Duman R. et al. Quality of life among patients with age-related severe macular degeneration assessed using the NEI-VFQ, HADS-A, HADS-D and SF-36 tests. A cross-sectional study. Sao Paulo Med J 2019; 137: 25-32 DOI: 10.1590/1516-3180.2018.0195071218.
• 7 Berdeaux GH, Nordmann JP, Colin E. et al. Vision-related quality of life in patients suffering from age-related macular degeneration. Am J Ophthalmol 2005; 139: 271-279 DOI: 10.1016/j.ajo.2004.09.028.
• 8 Mangione CM, Lee PP, Pitts J. et al. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol 1998; 116: 1496-1504 DOI: 10.1001/archopht.116.11.1496.
• 9 Mangione CM, Berry S, Spritzer K. et al. Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons. Arch Ophthalmol 1998; 116: 227-233 DOI: 10.1001/archopht.116.2.227.
• 10 Nickels S, Schuster AK, Singer S. et al. The National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25) – reference data from the German population-based Gutenberg Health Study (GHS). Health Qual Life Outcomes 2017; 15: 156 DOI: 10.1186/s12955-017-0732-7.
• 11 Toprak AB, Eser E, Güler C. [Quality of life instruments used in ophthalmology and the Turkish translation of National Eye Institute Visual Functioning Questionnaire (NEI-VFQ 25)]. Türk Oftalmoloji Gazetesi 2005; 35: 453-459
• 12 Mangione CM, Lee PP, Gutierrez PR. et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001; 119: 1050-1058 DOI: 10.1001/archopht.119.7.1050.
• 13 Franke GH, Esser J, Voigtländer A. et al. [The National Eye Institute Visual Function Questionnaire (NEI-VFQ)-First results on the psychometric testing of a quality of life measure for the visually impaired]. Z Med Psychol 1998; 7: 178-184
• 14 Wagenbreth C, Sabel BA, Tönnies S. et al. [The neuroophthalmic supplement to the NEI-VFQ: test statistics and validation with a cohort of patients with pre- and postchiasmatic damage]. Klin Monbl Augenheilkd 2011; 228: 971-978 DOI: 10.1055/s-0029-1246062.
• 15 Abdin AD, Suffo S, Bischoff-Jung M. et al. [Advantages of a designated IVI center for a German university eye hospital]. Ophthalmologe 2020; 117: 50-57 DOI: 10.1007/s00347-019-0911-5.
• 16 Lee JS, Lin KK, Hou CH. et al. Chinese Version of the Vision-Related Quality Of Life (NEI-VFQ-25) among Patients with Various Ocular Disorders: A Pilot Study. Medicina (Kaunas) 2022; 58: 602 DOI: 10.3390/medicina58050602.
• 17 Pauleikhoff D, Scheider A, Wiedmann P. et al. [Neovascular age-related macular degeneration in Germany. Encroachment on the quality of life and the financial implications]. Ophthalmologe 2009; 106: 242-251 DOI: 10.1007/s00347-008-1797-1799.
• 18 Ismayilova I, Turdaliyeva B, Aldasheva N. et al. Assessing the quality of life in age-related macular degeneration patients: a cross-sectional study in Kazakhstan. Acta Biomed 2022; 93: e2022299 DOI: 10.23750/abm.v93i6.13580.
• 19 Yuzawa M, Suzukamo Y, Zeon L. et al. [Quality of life evaluation of age-related macular degeneration]. Nippon Ganka Gakkai Zasshi 2004; 108: 368-374
• 20 Taylor DJ, Hobby AE, Binns AM. et al. How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review. BMJ Open 2016; 6: e011504 DOI: 10.1136/bmjopen-2016-011504.
• 21 Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes 2006; 4: 97 DOI: 10.1186/1477-7525-4-97.
• 22 Wong EY, Guymer RH, Hassell JB. et al. The experience of age-related macular degeneration. J Vis Impair Blind 2004; 98: 629-640 DOI: 10.1177/0145482X0409801007.
• 23 Abdin AD, Suffo S, Asi F. et al. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2019; 257: 1671-1677 DOI: 10.1007/s00417-019-04360-9.
• 24 Abdin AD, Aljundi W, El Jawhari K. et al. First year real life experience with intravitreal brolucizumab for treatment of refractory neovascular age-related macular degeneration. Front Pharmacol 2022; 13: 860784 DOI: 10.3389/fphar.2022.860784.
• 25 Kataja M, Hujanen P, Huhtala H. et al. Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting. Br J Ophthalmol 2018; 102: 959-965 DOI: 10.1136/bjophthalmol-2017-311055.
• 26 Brösel D, Sabel BA, Franke GH. et al. [The 2-Scale Model of the National Eye Institute Visual Function Questionnaire (NEI-VFQ) to Assess Vision-Related Quality of Life]. Klin Monbl Augenheilkd 2017; 234: 719-725 DOI: 10.1055/s-0042-109700.
• 27 Taylor DJ, Jones L, Binns AM. et al. ‘Youʼve got dry macular degeneration, end of story’: a qualitative study into the experience of living with non-neovascular age-related macular degeneration. Eye (Lond) 2020; 34: 461-473 DOI: 10.1038/s41433-019-0445-8.
• 28 Ahluwalia A, Shen LL, Bao Y. et al. The influence of the topographic location of geographic atrophy on vision-related quality of life in nonexudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2023; 261: 699-708 DOI: 10.1007/s00417-022-05849-6.
• 29 Kaltenegger K, Kuester S, Altpeter-Ott E. et al. Effects of home reading training on reading and quality of life in AMD-a randomized and controlled study. Graefes Arch Clin Exp Ophthalmol 2019; 257: 1499-1512 DOI: 10.1007/s00417-019-04328-9.
• 30 Waldstein SM, Simader C, Staurenghi G. et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology 2016; 123: 1521-1529 DOI: 10.1016/j.ophtha.2016.03.037.
• 31 Sharma S, Toth CA, Daniel E. et al. Comparison of age-related macular degeneration treatments trials research group. Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology 2016; 123: 865-875 DOI: 10.1016/j.ophtha.2015.12.002.